Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, is currently approved by the Food and Drug Administration for type 2 diabetes under the ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.